Keros Therapeutics, Inc. (KROS)
Nasdaq: KROS · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2016
Who runs Keros Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Seehra Jasbir
CHIEF EXECUTIVE OFFICER. First filing Apr 2020, latest Apr 6, 2026, 2 filings in all.
Officers reporting now
5
of 18 people with a filing in the last fifteen months
Directors reporting now
13
24 people on the record since 2020
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Cho Esther | Chief Legal Officer | Aug 2025 | Aug 20, 2026 | 2 · $100,000 |
| Lerner Lorena Raquel | Chief Scientific Officer | Aug 2025 | Aug 20, 2026 | 2 · $100,000 |
| Tanini Annita | Corp. Controller & VP, Finance | Aug 2026 | Aug 20, 2026 | 1 · $0.00 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Apr 2020 | Apr 6, 2026 | 1 · $100,000 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | Apr 2020 | Feb 26, 2026 | 1 · $100,000 |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Newton Charles W. | director | Mar 2026 | Aug 20, 2026 | 2 · $0.00 |
| Bienaime Jean Jacques | director | Jun 2024 | Aug 19, 2026 | none |
| Prener Anne | director | Jul 2026 | Jul 6, 2026 | none |
| Farzan Nima | director | Apr 2020 | Jun 8, 2026 | 1 · $0.00 |
| Knowles Julius | director | Apr 2020 | Jun 8, 2026 | 1 · $0.00 |
| Gray Mary Ann | director | Dec 2020 | Jun 5, 2026 | none |
| Seth Alpna | director | May 2023 | Jun 5, 2026 | 1 · $0.00 |
| Gordon Carl L | director | Apr 2020 | Dec 18, 2025 | none |
| Orbimed Advisors LLC | director | Apr 2020 | Dec 18, 2025 | none |
| Orbimed Capital Gp Vii LLC | director | Apr 2020 | Dec 18, 2025 | none |
| Orbimed Genesis Gp LLC | director | Apr 2020 | Dec 18, 2025 | none |
| Kariv Tomer | director | Apr 2020 | Oct 17, 2025 | none |
| Nussbaum Ran | director | Apr 2020 | Oct 17, 2025 | none |
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Pontifax (Cayman) IV L.P. | 10% owner | Apr 2020 | Oct 17, 2025 | none |
| Pontifax (China) IV L.P. | 10% owner | Apr 2020 | Oct 17, 2025 | 4 · $85.0M |
| Pontifax (Israel) IV, L.P. | 10% owner | Apr 2020 | Oct 17, 2025 | none |
| Pontifax Late Stage Fund L.P. | 10% owner | Apr 2020 | Oct 17, 2025 | none |
| Pontifax Late Stage Gp Ltd. | 10% owner | Apr 2020 | Oct 17, 2025 | none |
| Pontifax Management 4 G.P. (2015) Ltd. | 10% owner | Apr 2020 | Oct 17, 2025 | none |
| Adar1 Capital Management Gp, LLC | 10% owner | Apr 2025 | Oct 15, 2025 | none |
| Adar1 Capital Management, LLC | 10% owner | Apr 2025 | Oct 15, 2025 | none |
| Adar1 Partners, LP | 10% owner | Apr 2025 | Oct 15, 2025 | none |
| Schneeberger Daniel | 10% owner | Apr 2025 | Oct 15, 2025 | 3 · $95.7M |
Earlier names on the record9, newest filing first
Rovaldi Christopher · officer · last filing Feb 2025Chyung Yung H. · officer · last filing Feb 2025Cooper Simon Peter · officer · last filing Feb 2024Lachey Jennifer · officer · last filing Jul 2022Ordonez Claudia · officer · last filing Jun 2021Lazarus Alon · director · last filing Apr 2020Arkin Bio Venture Partners Ltd. · 10% owner · last filing Apr 2020Arkin Bio Ventures Limited Partnership · 10% owner · last filing Apr 2020Arkin Moshe · 10% owner · last filing Apr 2020
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.